The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials. With the help of the Biomarkers Consortium ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback